Monday's Health Winners & Losers - TheStreet

Monday's Health Winners & Losers

Dendreon continues to advance, after Friday's good news from the FDA on its prostate drug.
Publish date:

Updated from 12:58 p.m. EDT



was one of Monday's best performers. On Friday, the Food and Drug Administration said the company's prostate cancer vaccine treatment, Provenge, was safe and effective in treating prostate cancer. A final decision from the FDA is expected on May 15. Shares of Dendreon, which soared 147% on Friday, closed up $1.37, or 10.6%, to $14.30.


(NVAX) - Get Report

jumped 17.8% after the company said its vaccine prevention for H9N2, another strain of the avian flu virus, was effective when tested on animals. Shares of Novavax gained 46 cents to $3.05.

Shares of



were also higher after Jefferies upgraded the stock to buy from hold. The firm also upped Cephalon's stock price target to $88 from $69. The stock climbed $4.75, or 6.7%, to $75.96.

On the other hand,

Bruker BioSciences

(BRKR) - Get Report

was losing ground after Bear Stearns lowered its rating on the company to underperform from peer perform. Shares of Bruker were recently down 26 cents, or 2.5%, to $10.26.

Among other health care winners,


(CELG) - Get Report

added 2.6% to $53.80.

MedcoHealth Solutions


was gaining 1.8% to $73.84.


(MRK) - Get Report

was higher by 1.9% at $45.01.

Among decliners,

CV Therapeutics


shed 4.5% to $7.62.



was off 2.2% to $35.60, and



was lower by 0.4% at $25.42.